Free Trial
OTCMKTS:IVBXF

Innovent Biologics (IVBXF) Stock Price, News & Analysis

$4.97
-0.13 (-2.55%)
(As of 05/21/2024 ET)
Today's Range
$4.97
$5.09
50-Day Range
$4.28
$5.48
52-Week Range
$3.55
$6.41
Volume
5,200 shs
Average Volume
181,592 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IVBXF stock logo

About Innovent Biologics Stock (OTCMKTS:IVBXF)

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

IVBXF Stock Price History

IVBXF Stock News Headlines

Innovent Biologics (OTCMKTS:IVBXF) Shares Down 0.7%
Innovent Biologics Inc IVBXF
See More Headlines
Receive IVBXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovent Biologics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:IVBXF
CIK
N/A
Fax
N/A
Employees
4,872
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. De-Chao Yu Ph.D. (Age 60)
    Co-Founder, Chairman & CEO
    Comp: $4.55M
  • Mr. Hao Xi Ede (Age 65)
    Executive Director & Fund Managing Partner
    Comp: $961.61k
  • Dr. Yong Jun Liu M.D. (Age 55)
    Ph.D., President
  • Ms. Fei You (Age 45)
    Chief Financial Officer
  • Ms. Vivian Zhang
    Chief People Officer & GM
  • Mr. Min Liu
    Chief Commercial Officer
  • Mr. Dongming Wang
    Senior Vice President
  • Mr. Blake Salisbury
    Senior Vice President
  • Dr. Hui Zhou Ph.D.
    Senior Vice President
  • Ms. Yanju Wang (Age 35)
    Joint Company Secretary

IVBXF Stock Analysis - Frequently Asked Questions

Should I buy or sell Innovent Biologics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Innovent Biologics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IVBXF shares.
View IVBXF analyst ratings
or view top-rated stocks.

How have IVBXF shares performed in 2024?

Innovent Biologics' stock was trading at $4.92 at the beginning of 2024. Since then, IVBXF shares have increased by 1.0% and is now trading at $4.97.
View the best growth stocks for 2024 here
.

How do I buy shares of Innovent Biologics?

Shares of IVBXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IVBXF) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners